The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Subscribe To Our Newsletter & Stay Updated
